The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer

Ruth O’Regan, MD
Published Online:2:16 PM, Mon May 15, 2017

Ruth O’Regan, MD, division head of hematology and oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment and were treated with an aromatase inhibitor.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.